Maxwell Oluwole Akanbi

Maxwell Oluwole Akanbi

Auto-generated profile, based on publicly available information

Maxwell Oluwole Akanbi

Department of Medicine, Jos University Teaching Hospital, Jos, Nigeria

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2018 in Addiction
Verified
Journal Article
Open access
PDF file
MAMaxwell Oluwole Akanbi
Maxwell Oluwole Akanbi
ACAllison Jane Carroll
Allison Jane Carroll
CAChad Achenbach
Chad Achenbach
LOLinda Catherine O'Dwyer
Linda Catherine O'Dwyer
NJNeil Jordan
Neil Jordan
RMRobert Murphy
Robert Murphy
Aims: To summarize evidence for the efficacy of smoking cessation interventions in low‐ and middle‐income countries (LMICs).Design: Systematic review and meta‐analysis of randomized controlled trials.Setting: LMICs as defined by the World Bank.Participants: Adult current cigarette smokers residing in LMICs.Interventions: Behavioral and/or pharmacotherapy smoking cessation interventions.Measurements: PubMed MEDLINE, EMBASE (embase.com), Cochrane Central Register of Controlled Trials (Wiley), PsycINFO (Ebsco), SciELO, WHO Global Index Medicus and Scopus were searched from inception to 4 April 2018. Only studies with at least 6 months of follow‐up were included. We used the most rigorous assessment of abstinence reported by each study. Effect sizes were computed from abstracted data. Where possible, a meta‐analysis was performed using Mantel–Haenzel random‐effect models reporting odds ratios (OR) and 95% confidence intervals (CI).Findings: Twenty‐four randomized controlled trials were included. Six investigated the efficacy of pharmacological agents. Four trials that compared nicotine replacement therapy (NRT) to placebo found NRT improved cessation rates (n : NRT 546, control 684, OR = 1.76, 95% CI = 1.30–2.77, P < 0.001, I2 = 13%). Eight trials found that behavioral counseling was more effective than minimal interventions (e.g. brief advice); n : Counseling 2941, control 2794, OR = 6.87, 95% CI = 4.18–11.29, P < 0.001, I2 = 67%). There was also evidence of the benefit of brief advice over usual care (n : Brief advice 373, control 355, OR = 2.46, 95% CI = 1.56–3.88, P < 0.001, I2 = 0%).Conclusion: Nicotine replacement therapy, behavioral counseling and brief advice appear to be effective in aiding smoking cessation in low‐ and middle‐income countries. There is limited rigorous research on other smoking cessation interventions in these regions.

1 January 2012
Verified
Closed access
MAMaxwell O. Akanbi
Maxwell O. Akanbi
AOAmaka N. Ocheke
Amaka N. Ocheke
PAPatricia A. Agaba
Patricia A. Agaba
CDComfort A. Daniyam
Comfort A. Daniyam
EAEmmanuel I. Agaba
Emmanuel I. Agaba
CUChristiana O. Ukoli
Christiana O. Ukoli

1 January 2013 in Nigerian Medical Journal
Verified
Journal Article
Open access
PDF file
OOObianuju Ozoh
Obianuju Ozoh
NONjideka U Okubadejo
Njideka U Okubadejo
MAMaxwellO Akanbi
MaxwellO Akanbi
MDMichelle G Dania
Michelle G Dania
Background: The burden of obstructive sleep apnea among commercial drivers in Nigeria is not known. Aim: To assess the prevalence of high risk of obstructive sleep apnea (OSA) and excessive daytime sleepiness (EDS) among intra-city commercial drivers. Setting and Design: A descriptive cross-sectional study in three major motor parks in Lagos metropolis. Materials and Methods: Demographic, anthropometric and historical data was obtained. The risk of OSA and EDS was assessed using the STOP BANG questionnaire and the Epworth Sleepiness Scale, respectively. Statistical Analysis: The relationship between the OSA risk, EDS risk and past road traffic accident (RTA) was explored using the Pearson's chi square. Independent determinants of OSA risk, EDS risk and past RTA, respectively, were assessed by multiple logistic regression models. Result: Five hundred male commercial drivers (mean age (years) ±SD = 42.36 ± 11.17 and mean BMI (kg/m 2 ) ±SD = 25.68 ± 3.79) were recruited. OSA risk was high in 244 (48.8%) drivers and 72 (14.4%) had EDS. There was a positive relationship between OSA risk and the risk of EDS (Pearson's X 2 = 28.2, P < 0.001). Sixty-one (12.2%) drivers had a past history of RTA but there was no significant relationship between a past RTA and either OSA risk (X 2 = 2.05, P = 0.15) or EDS risk (X 2 = 2.7, P = 0.1), respectively. Abdominal adiposity, regular alcohol use and EDS were independent determinants of OSA risk while the use of cannabis and OSA risk were independent determinants of EDS. No independent risk factor for past RTA was identified. Conclusion: A significant proportion of commercial drivers in Lagos metropolis are at high risk of OSA and EDS.

30 May 2017 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
MAMaxwell Oluwole Akanbi
Maxwell Oluwole Akanbi
CAChad Achenbach
Chad Achenbach
BTBabafemi Taiwo
Babafemi Taiwo
JIJohn Idoko
John Idoko
AAAgatha Ani
Agatha Ani
RMRobert Leo Murphy
Robert Leo Murphy
Xpert MTB/Rif (Xpert) is described as a game changer in tuberculosis (TB) control. We evaluated the impact of Xpert on diagnosis, time to treatment, and treatment outcome among patients with HIV associated TB in Nigeria. Adults with HIV being evaluated for pulmonary TB (PTB) were consecutively enrolled into the study cohort. At baseline, expectorated sputa were examined using Xpert and smear microscopy for Mycobacterium tuberculosis (MTB) and acid fast bacilli, respectively. Patients diagnosed with TB were followed-up until 6 months post TB diagnosis. TB was defined as sputum positive by smear microscopy, Xpert detection of MTB (bacteriologically confirmed case), or clinician diagnosed TB with initiation of full TB treatment (clinical diagnosis). Time to treatment was time from first clinic presentation for TB evaluation to initiation of TB treatment. We examined the proportion PTB patients with a positive Xpert result and compared time to TB treatment and outcome of TB treatment in patients based on sputum test results. A total of 310 adults with HIV were enrolled. The median CD4 cell count was 242 (interquartile range (IQR) 120–425) cells/mm3 and 88.1% were receiving antiretroviral therapy (ART). PTB was diagnosed in 76 (24.5%) patients, with 71 (93.4%) being bacteriologically confirmed. Among patients with PTB, 56 (73.7%) were Xpert positive. Median time to treatment was 5 (IQR 2–8) days and 12 (IQR 5–35) days in patient with and without Xpert positive results, respectively; p = 0.005. Overall 73.1% had symptom free survival at 6 months post PTB treatment initiation with no significant differences observed based on TB test method. 10 (14.9%) died within 6 months of TB treatment initiation. In analysis adjusted for age, sex, and mode of diagnosis (Xpert positive or negative), only ART use independently predicted mortality (AOR 0.10; 95% CI 0.01–0.93). The use of Xpert for routine care reduced time to PTB treatment, but did not improve survival in patients with HIV treated for susceptible PTB.

1 September 2012 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
LDLana Dinic
Lana Dinic
PAPatrick Akande
Patrick Akande
EIEmmanuel Oni Idigbe
Emmanuel Oni Idigbe
AAAgatha Ani
Agatha Ani
DODan Onwujekwe
Dan Onwujekwe
PKPhyllis Jean Kanki
Phyllis Jean Kanki
Tuberculosis (TB) is the most common opportunistic infection in human immunodeficiency virus (HIV)-infected patients and the emergence of drug-resistant tuberculosis (DR-TB) is a growing problem in resource-limited settings. Adequate infrastructure for testing drug sensitivity and sufficient evidence of first-line resistance are currently unavailable in Nigeria. We collected sputum samples from HIV-infected patients enrolled in the Harvard PEPFAR/APIN Plus program over 12 months at two PEPFAR antiretroviral therapy (ART) clinics in the southwest and north central regions in Nigeria. Smear-positive sputum samples were submitted for GenoType MTBDRplus testing ( n = 415); mutations were confirmed through sequencing. Our results show high rates of DR-TB in Nigerian HIV-infected individuals (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]). Total RIF resistance indicative of MDR-TB in treatment-naive patients was 5.52%, far exceeding the World Health Organization predictions (0 to 4.3%). RIF resistance was found in 6/213 (2.8%) cases, INH resistance was found in 3/215 (1.4%) cases, and MDR-TB was found in 8/223 (3.6%) cases. We found significantly different amounts of DR-TB by location (18.18% in the south of the country versus 3.91% in the north central region [ P < 0.01]). Furthermore, RIF resistance was genetically distinct, suggesting possible location-specific strains are responsible for the transmission of drug resistance ( P < 0.04). Finally, GenoType MTBDRplus correctly identified the drug-resistant samples compared to sequencing in 96.8% of cases. We found that total DR-TB in HIV-infection is high and that transmission of drug-resistant TB in HIV-infected patients in Nigeria is higher than predicted.

1 June 2013 in AIDS Research and Human Retroviruses
Verified
Journal Article
Closed access
MAMaxwell O. Akanbi
Maxwell O. Akanbi
CAChad J. Achenbach
Chad J. Achenbach
JFJoe Feinglass
Joe Feinglass
BTBabafemi Taiwo
Babafemi Taiwo
AOAdamu Onu
Adamu Onu
RMRobert L. Murphy
Robert L. Murphy
Our objective was to determine tuberculosis (TB) incidence and evaluate TB risk in adults after one or more years of use of combination antiretroviral therapy (cART) through a retrospective cohort study in Jos, Nigeria. We studied a cohort of HIV-infected adults treated with ART for at least 1 year. Based on immunologic and virologic responses to ART, patients were categorized into four groups: CD4 T cell count ≥350 cells/mm 3 and HIV-1 RNA level ≤400 copies/ml (group 1), CD4 T cell count ≥350 cells/mm 3 and HIV-1 RNA level >400 copies/ml (group 2), CD4 T cell count <350 cells/mm 3 and HIV-1 RNA level ≤400 copies/ml (group 3), and CD4 T cell count 400 copies/ml (group 4). Time to incident TB for the four groups was analyzed using the Kaplan–Meier method. Cox regression models were used to evaluate predictors of incident TB. In this cohort of 5,093 HIV-infected adults, of which 68.4% were female, with a mean age 35.1 years (standard deviation 9.1 years), we observed 98 cases of incident TB during 4 years and 3 months of follow-up. The overall TB incidence rate was 8.7 cases/1,000 patient-years of follow-up. Adjusted hazards for incident TB were 2.11 (95% CI 0.97–4.61), 2.05 (95% CI 1.10–3.79), and 3.65 (95% CI 1.15–5.06) in group 2, 3, and 4 patients, respectively, compared to group 1. Tuberculosis incidence in patients on ART is driven by poor immunologic and/or virologic response. Optimization of HIV treatment should be prioritized to reduce the burden of TB in this high-risk population.